Bombay HC backs GSK in Paxil trademark row against Shreya Life Sciences

The Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medicinal preparations. It argued that despite getting the mark more than two decades ago, Shreya Life Sciences had never used it and hence, under Section 47 of the Trade Marks Act, the registration was liable to be removed from the register of trade marks on account of non-use.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9tGdrAP
via IFTTT